199 related articles for article (PubMed ID: 23385614)
21. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract][Full Text] [Related]
22. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
[TBL] [Abstract][Full Text] [Related]
24. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
25. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
Verstovsek S; Talpaz M; Ritchie E; Wadleigh M; Odenike O; Jamieson C; Stein B; Uno T; Mesa RA
Leukemia; 2017 Feb; 31(2):393-402. PubMed ID: 27479177
[TBL] [Abstract][Full Text] [Related]
26. Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y; McLornan DP; Harrison CN
Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
[TBL] [Abstract][Full Text] [Related]
27. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Stein BL; Swords R; Hochhaus A; Giles F
Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
[TBL] [Abstract][Full Text] [Related]
28. Myelofibrosis in 2019: moving beyond JAK2 inhibition.
Schieber M; Crispino JD; Stein B
Blood Cancer J; 2019 Sep; 9(9):74. PubMed ID: 31511492
[TBL] [Abstract][Full Text] [Related]
29. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
30. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
31. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman G; Mascarenhas J
Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
[TBL] [Abstract][Full Text] [Related]
32. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D; Mascarenhas J
Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
[TBL] [Abstract][Full Text] [Related]
33. Emerging targeted therapies in myelofibrosis.
Barosi G
Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib for the treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
[TBL] [Abstract][Full Text] [Related]
35. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.
Vannucchi AM
Leuk Res; 2009 Dec; 33(12):1581-3. PubMed ID: 19573914
[TBL] [Abstract][Full Text] [Related]
36. JAK2 inhibitors in myelofibrosis.
Pardanani A
Clin Adv Hematol Oncol; 2011 Nov; 9(11):856-8. PubMed ID: 22252617
[No Abstract] [Full Text] [Related]
37. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
38. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
39. A phase 1 study of the Janus kinase 2 (JAK2)
Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
[TBL] [Abstract][Full Text] [Related]
40. Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):990-992. PubMed ID: 29651917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
